Cost effectiveness of decentralized care model for managing multi-drug-resistant tuberculosis in low- and middle-income countries: a systematic review protocol.
Journal
JBI evidence synthesis
ISSN: 2689-8381
Titre abrégé: JBI Evid Synth
Pays: United States
ID NLM: 101764819
Informations de publication
Date de publication:
28 Sep 2023
28 Sep 2023
Historique:
medline:
2
10
2023
pubmed:
2
10
2023
entrez:
2
10
2023
Statut:
aheadofprint
Résumé
The purpose of this systematic review is to assess the economic evaluation of a decentralized care model compared to a centralized model for multi-drug-resistant tuberculosis (MDR-TB) in low- and middle-income countries (LMICs). Diseases that affect physiological health create a burden on human livelihoods and the economy. There is a lack of studies examining the economic evaluation of MDR-TB across different countries, and no published or ongoing reviews on MDR-TB in LMICs have been identified. Studies will be eligible if they include both patients receiving centralized care and patients receiving decentralized care for MDR-TB in LMICs. A preliminary search of MEDLINE (PubMed) was undertaken using MeSH terms, such as MDR-TB, economic evaluation, therapeutics, LMICs. Two reviewers will independently screen the titles, abstracts, and full text against the inclusion criteria. Disagreements will be resolved through discussion or with a third reviewer. The JBI checklist for economic evaluations will be utilized to evaluate the methodological quality. Data will be extracted using a modified JBI data extraction form for economic evaluations. The Dominance Ranking Matrix, developed by JBI for economic evaluations, will be used to summarize and compare the results of different types of economic evaluations (cost-effectiveness, cost-benefit analysis, cost-utility analysis, or cost-minimization analysis). Cost per quality-adjusted life year gained and cost per disability-adjusted life year averted will be measures for economic evaluation. The Grading of Recommendations, Assessment, Development, and Evaluation (GRADE) approach will be used to assess the certainty of economic evidence. PROSPERO CRD42022368696.
Identifiants
pubmed: 37779435
doi: 10.11124/JBIES-23-00023
pii: 02174543-990000000-00215
doi:
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Informations de copyright
Copyright © 2023 JBI.
Déclaration de conflit d'intérêts
The authors declare no conflict of interest.
Références
World Health Organization. Global tuberculosis report, 2018 [internet]. WHO; 2018 [cited 2022 Nov 1]. Available from: https://www.who.int/publications/i/item/9789241565646.
World Health Organization. Companion handbook to the WHO guidelines for the programmatic management of drug-resistant tuberculosis [internet]. WHO; 2014 [cited 2022 Nov 1]. Available from: https://apps.who.int/iris/bitstream/handle/10665/130918/9789241548809_eng.pdf?sequence=1.
World Health Organization. Global tuberculosis report 2020 [internet]. WHO; 2020 [cited 2022 Dec 15]. Available from: https://www.who.int/publications/i/item/9789240013131.
World Health Organization. Tuberculosis patient cost surveys: a handbook [internet]. WHO; 2017 [cited 2022 Nov 1]. Available from: http:// www.who.int/tb/publications/patient_cost_surveys.
Ruan YZ, Li RZ, Wang XX, Wang LX, Sun Q, Chen C, et al. The affordability for patients of a new universal MDR-TB coverage model in China. Int J Tuberc Lung Dis 2016;20(5):638–644.
World Health Organization. Global tuberculosis report 2012 [internet]. WHO; 2012 [cited 2022 Nov 1]. Available from: https://www.who.int/publications/i/item/9789241564502.
World Health Organization. Countries are spending more on health, but people are still paying too much out of their own pockets [internet]. WHO; 2019 [cited 2022 Dec 15]. Available from: https://www.who.int/news/item/20-02-2019-countries-are-spending-more-on-health-but-people-are-still-paying-too-much-out-of-their-own-pockets.
Monedero-Recuero I, Gegia M, Wares DF, Chadha SS, Mirzayev F. Situational analysis of 10 countries with a high burden of drug-resistant tuberculosis 2 years post-UNHLM declaration: progress and setbacks in a changing landscape. Int J Infect Dis 2021;108:557–567.
Sharma SK, Mohan A. Multidrug-resistant tuberculosis. Indian J Med Res 2004;120(4):354–376.
World Health Organization. Guidelines for the programmatic management of drug-resistance tuberculosis—2011 update [internet]. WHO; 2011 [cited 2023 May 11]. Available from: https://www.who.int/publications/i/item/9789241501583.
Keshavjee S, Farmer PE. Picking up the pace — scale-up of MDR tuberculosis treatment programs. N Engl J Med 2010;363(19):1781–1784.
World Health Organization. Tuberculosis [internet]. WHO; 2023 [cited 2023 May 11]. Available from: https://www.who.int/news-room/fact-sheets/detail/tuberculosis.
John D, Chatterjee P, Murthy S, Bhat R, Musa BM. Cost effectiveness of decentralised care model for managing MDR-TB in India. Indian J Tuberc 2018;65(3):208–217.
Zawedde-Muyanja S, Reuter A, Tovar MA, Hussain H, Loando Mboyo A, Detjen AK, et al. Provision of decentralized TB Care Services: A detect–treat–prevent strategy for children and adolescents affected by TB. Pathogens 2021;10(12):1568.
Ho J, Byrne AL, Linh NN, Jaramillo E, Fox GJ. Decentralized care for multidrug-resistant tuberculosis: a systematic review and meta-analysis. Bull World Health Organ 2017;95(8):584–593.
Tanimura T, Jaramillo E, Weil D, Raviglione M, Lonnroth K. Financial burden for tuberculosis patients in low- and middle-income countries: a systematic review. Eur Respir J 2014;43(6):1763–1775.
Fitzpatrick C, Floyd K. A systematic review of the cost and cost effectiveness of treatment for multidrug-resistant tuberculosis. PharmacoEconomics 2012;30(1):63–80.
Zhang T, Lv CF, Wang J, Zheng WB, Lu LZ, Liu SJ, et al. Direct tuberculosis drug susceptibility testing: time-saving and cost-effective in detecting MDR-TB. Int J Tuberc Lung Dis 2016;20(3):323–328.
Alemayehu S, Yigezu A, Hailemariam D, Hailu A. Cost-effectiveness of treating multidrug-resistant tuberculosis in treatment initiative centers and treatment follow-up centers in Ethiopia. PLoS ONE 2020;15(7):e0235820.
Resch SC, Salomon JA, Murray M, Weinstein MC. Cost-effectiveness of treating multidrug-resistant tuberculosis. PLoS Med 2006;3(7):e241.
Bada FO, Okpokoro E, Blok N, Meribole E, Dutt S, Dakum P, et al. Cost of three models of care for drug-resistant tuberculosis patients in Nigeria. BMC Infect Dis 2019;19(1):41.
Streak Gomersall J, Tertilus Jadotte Y, Xue Y, Lockwood S, Riddle D, Preda A. Chapter 6: Systematic Reviews of Economic Evidence [internet] Aromataris E, Munn Z. JBI Manual for Evidence Synthesis. JBI; 2020 [cited 2022 Nov 3]. Available from: https://synthesismanual.jbi.global.
Hamadeh N, Rompaey CV, Metreau E, Eapen SG. New World Bank country classifications by income level: 2022–2023 [internet]. World Bank; 2022 [cited 2023 Jan 06]. Available from: https://blogs.worldbank.org/opendata/new-world-bank-country-classifications-income-level-2022-2023.
McGowan J, Sampson M, Salzwedel DM, Cogo E, Foerster V, Lefebvre C. PRESS Peer Review of Electronic Search Strategies: 2015 Guideline Statement. J Clin Epidemiol 2016;75:40–46.
Page MJ, McKenzie JE, Bossuyt PM, Boutron I, Hoffmann TC, Mulrow CD, et al. The PRISMA 2020 statement: an updated guideline for reporting systematic reviews. BMJ 2021;372:n71.
Brunetti M, Shemilt I, Pregno S, Vale L, Oxman AD, Lord J, et al. GRADE guidelines: 10. Considering resource use and rating the quality of economic evidence. J Clin Epidemiol 2013;66(2):140–150.